Yi-Chien Tsai
Overview
Explore the profile of Yi-Chien Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hsieh Y, Guan H, Lin C, Huang T, Chuankhayan P, Chen N, et al.
JACS Au
. 2024 Jun;
4(6):2130-2150.
PMID: 38938812
Monoclonal antibodies (mAbs) have gradually dominated the drug markets for various diseases. Improvement of the therapeutic activities of mAbs has become a critical issue in the pharmaceutical industry. A novel...
2.
Chang Y, Prompsy P, Kimeswenger S, Tsai Y, Ignatova D, Pavlova O, et al.
Nat Commun
. 2024 Jan;
15(1):752.
PMID: 38272918
Cancer-associated immune dysfunction is a major challenge for effective therapies. The emergence of antibodies targeting tumor cell-surface antigens led to advancements in the treatment of hematopoietic malignancies, particularly blood cancers....
3.
Ettinger M, Burner T, Sharma A, Chang Y, Lackner A, Prompsy P, et al.
Nat Commun
. 2023 Nov;
14(1):7470.
PMID: 37978298
Darier disease (DD) is a rare, inherited multi-organ disorder associated with mutations in the ATP2A2 gene. DD patients often have skin involvement characterized by malodorous, inflamed skin and recurrent, severe...
4.
Tsai Y, Schlaepfer T, Ignatova D, Chang Y, Valaperti A, Amarov B, et al.
Br J Dermatol
. 2023 Jul;
189(5):603-611.
PMID: 37409661
Background: Extracorporeal photopheresis (ECP) has emerged as a systemic first-line immunomodulatory therapy in leukaemic cutaneous T-cell lymphoma (L-CTCL) and is now beginning to be utilized in other T-cell-mediated diseases. Although...
5.
CD38 Targeting Holds Potential for the Treatment of Aggressive Refractory Cutaneous T-Cell Lymphomas
Pavlova O, Tsai Y, Chang Y, Vonow Eisenring M, Guenova E
J Invest Dermatol
. 2023 Mar;
143(7):1122-1126.
PMID: 36933969
No abstract available.
6.
Jin Q, Gutierrez Diaz B, Pieters T, Zhou Y, Narang S, Fijalkwoski I, et al.
Sci Adv
. 2022 Dec;
8(49):eabq8437.
PMID: 36490346
Dysregulation of kinase signaling pathways favors tumor cell survival and therapy resistance in cancer. Here, we reveal a posttranslational regulation of kinase signaling and nuclear receptor activity via deubiquitination in...
7.
Jomrich G, Kollmann D, Wilfing L, Radosavljevic S, Ramazanova D, Ristl R, et al.
Eur Surg
. 2021 Dec;
53(6):287-293.
PMID: 34868284
Background: The effects of cytotoxic chemotherapy on the expression of programmed death ligand 2 (PD-L2) are unknown and little is known about how the tumor microenvironment changes following neoadjuvant chemotherapy...
8.
Jomrich G, Kollmann D, Ramazanova D, Ristl R, Grose R, Ilhan-Mutlu A, et al.
Eur J Surg Oncol
. 2021 Aug;
48(2):383-390.
PMID: 34404561
Background: The effects of cytotoxic chemotherapy on the expression of programmed cell death 1 (PD-1) and its ligand (PD-L1) in cancer cells and peritumoral cells are unclear. The aim of...
9.
Bhansali R, Rammohan M, Lee P, Laurent A, Wen Q, Suraneni P, et al.
J Clin Invest
. 2021 Jan;
131(1).
PMID: 33393494
DYRK1A is a serine/threonine kinase encoded on human chromosome 21 (HSA21) that has been implicated in several pathologies of Down syndrome (DS), including cognitive deficits and Alzheimer's disease. Although children...
10.
Mezzatesta C, Abduli L, Guinot A, Eckert C, Schewe D, Zaliova M, et al.
Blood Cancer J
. 2020 Jun;
10(6):72.
PMID: 32591499
Despite rapid progress in genomic profiling in acute lymphoblastic leukemia (ALL), identification of actionable targets and prediction of response to drugs remains challenging. To identify specific vulnerabilities in ALL, we...